BCR‐ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein. Issue 3 (2nd December 2013)

• Record Type: Journal Article
• Authors: Buffa, Pietro; Romano, Chiara; Pandini, Alessandro; Massimino, Michele; Tirrò, Elena; Di Raimondo, Francesco; Manzella, Livia; Fraternali, Franca; Vigneri, Paolo G.
• Is Part Of: FASEB journal. Volume 28:Issue 3(2014)
• Page Start: 1221
• Page End: 1236
• Publication Date: 2013-12-02
• Subjects: CML -- molecular dynamics -- mutations -- resistance -- TKIs; Biology -- Periodicals; Biology, Experimental -- Periodicals; 570
• DOI: 10.1096/fj.13-236992
• Languages: English
• ISSNs: 0892-6638

Abstract

Abstract : Patients with chronic myeloid leukemia in whom tyrosine kinase inhibitors (TKIs) fail often present mutations in the BCR‐ABL catalytic domain. We noticed a lack of substitutions involving 4 amino acids (E286, M318, I360, and D381) that form hydrogen bonds with ponatinib. We therefore introduced mutations in each of these residues, either preserving or altering their physicochemical properties. We found that E286, M318, I360, and D381 are dispensable for ABL and BCR‐ABL protein stability but are critical for preserving catalytic activity. Indeed, only a "conservative" I360T substitution retained kinase proficiency and transforming potential. Molecular dynamics simulations of BCR‐ABL I360T revealed differences in both helix αC dynamics and protein‐correlated motions, consistent with a modified ATP‐binding pocket. Nevertheless, this mutant remained sensitive to ponatinib, imatinib, and dasatinib. These results suggest that changes in the 4 BCR‐ABL residues described here would be selected against by a lack of kinase activity or by maintained responsiveness to TKIs. Notably, amino acids equivalent to those identified in BCR‐ABL are conserved in 51% of human tyrosine kinases. Hence, these residues may represent an appealing target for the design of pharmacological compounds that would inhibit additional oncogenic tyrosine kinases while avoiding the emergence of resistance due to point mutations.—Buffa, P., Romano, C., Pandini, A., Massimino, M., Tirrò, E., Di Raimondo, F., Manzella, L., Fraternali, F., Vigneri, P. G. BCR‐ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein. FASEB J. 28, 1221–1236 (2014). www.fasebj.org